Cargando…

High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response

SIMPLE SUMMARY: Electroporation is a method of treatment in which electrical pulses are generated and applied to a cell, resulting in temporary (reversible electroporation, RE) or permanent (irreversible electroporation, IRE) changes to the structure of the cell, depending on the pulse parameters ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyons, Phoebe, Polini, Dana, Russell-Ryan, Kate, Clover, A. James P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296441/
https://www.ncbi.nlm.nih.gov/pubmed/37370822
http://dx.doi.org/10.3390/cancers15123212
_version_ 1785063659426283520
author Lyons, Phoebe
Polini, Dana
Russell-Ryan, Kate
Clover, A. James P.
author_facet Lyons, Phoebe
Polini, Dana
Russell-Ryan, Kate
Clover, A. James P.
author_sort Lyons, Phoebe
collection PubMed
description SIMPLE SUMMARY: Electroporation is a method of treatment in which electrical pulses are generated and applied to a cell, resulting in temporary (reversible electroporation, RE) or permanent (irreversible electroporation, IRE) changes to the structure of the cell, depending on the pulse parameters applied. There has been increasing interest in manipulating the pulse parameters used to deliver successful electroporation for cutaneous malignancies in order to reduce muscle contractions and pain associated with traditional low-frequency electrochemotherapy (LF-ECT), which often requires general anaesthesia. Higher-frequency electroporation with biphasic waves successfully permeabilises the cell membrane, usually without causing these side effects, thus allowing treatment to be delivered under local anaesthetic. This permits a wide range of patients to be safely treated, including those for which general anaesthetic is a contra-indication. This article aims to demonstrate the safety and efficacy of high-frequency electroporation, as well as equivalence and good tolerability in comparison to traditional electrochemotherapy. ABSTRACT: High-frequency electroporation (HF-EP) with chemotherapy is a novel therapy proposed for both curative and palliative treatment of cutaneous malignancies. The use of high-frequency biphasic pulses is thought to reduce the painful muscle contractions associated with traditional electrochemotherapy (ECT), allowing treatment administration under local anaesthesia. This proof-of-concept study investigated the efficacy and tolerability of HF-EP protocols on a variety of cutaneous malignancies. A total of 97 lesions of five different histological subtypes were treated across 25 patients. At 12 weeks post-treatment, a 91.3% overall lesion response rate was observed (complete response: 79%; partial response: 12.3%), with excellent intraprocedural patient tolerability under local anaesthetic. HF-EP with chemotherapy shows promising results regarding tumour response rates for cutaneous malignancies of varying histological subtypes when compared to traditional ECT protocols. Improved patient tolerability is important, increasing the possibility of treatment delivery under local anaesthesia and potentially broadening the treatment envelope for patients with cutaneous malignancies.
format Online
Article
Text
id pubmed-10296441
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102964412023-06-28 High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response Lyons, Phoebe Polini, Dana Russell-Ryan, Kate Clover, A. James P. Cancers (Basel) Article SIMPLE SUMMARY: Electroporation is a method of treatment in which electrical pulses are generated and applied to a cell, resulting in temporary (reversible electroporation, RE) or permanent (irreversible electroporation, IRE) changes to the structure of the cell, depending on the pulse parameters applied. There has been increasing interest in manipulating the pulse parameters used to deliver successful electroporation for cutaneous malignancies in order to reduce muscle contractions and pain associated with traditional low-frequency electrochemotherapy (LF-ECT), which often requires general anaesthesia. Higher-frequency electroporation with biphasic waves successfully permeabilises the cell membrane, usually without causing these side effects, thus allowing treatment to be delivered under local anaesthetic. This permits a wide range of patients to be safely treated, including those for which general anaesthetic is a contra-indication. This article aims to demonstrate the safety and efficacy of high-frequency electroporation, as well as equivalence and good tolerability in comparison to traditional electrochemotherapy. ABSTRACT: High-frequency electroporation (HF-EP) with chemotherapy is a novel therapy proposed for both curative and palliative treatment of cutaneous malignancies. The use of high-frequency biphasic pulses is thought to reduce the painful muscle contractions associated with traditional electrochemotherapy (ECT), allowing treatment administration under local anaesthesia. This proof-of-concept study investigated the efficacy and tolerability of HF-EP protocols on a variety of cutaneous malignancies. A total of 97 lesions of five different histological subtypes were treated across 25 patients. At 12 weeks post-treatment, a 91.3% overall lesion response rate was observed (complete response: 79%; partial response: 12.3%), with excellent intraprocedural patient tolerability under local anaesthetic. HF-EP with chemotherapy shows promising results regarding tumour response rates for cutaneous malignancies of varying histological subtypes when compared to traditional ECT protocols. Improved patient tolerability is important, increasing the possibility of treatment delivery under local anaesthesia and potentially broadening the treatment envelope for patients with cutaneous malignancies. MDPI 2023-06-16 /pmc/articles/PMC10296441/ /pubmed/37370822 http://dx.doi.org/10.3390/cancers15123212 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lyons, Phoebe
Polini, Dana
Russell-Ryan, Kate
Clover, A. James P.
High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response
title High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response
title_full High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response
title_fullStr High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response
title_full_unstemmed High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response
title_short High-Frequency Electroporation and Chemotherapy for the Treatment of Cutaneous Malignancies: Evaluation of Early Clinical Response
title_sort high-frequency electroporation and chemotherapy for the treatment of cutaneous malignancies: evaluation of early clinical response
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296441/
https://www.ncbi.nlm.nih.gov/pubmed/37370822
http://dx.doi.org/10.3390/cancers15123212
work_keys_str_mv AT lyonsphoebe highfrequencyelectroporationandchemotherapyforthetreatmentofcutaneousmalignanciesevaluationofearlyclinicalresponse
AT polinidana highfrequencyelectroporationandchemotherapyforthetreatmentofcutaneousmalignanciesevaluationofearlyclinicalresponse
AT russellryankate highfrequencyelectroporationandchemotherapyforthetreatmentofcutaneousmalignanciesevaluationofearlyclinicalresponse
AT cloverajamesp highfrequencyelectroporationandchemotherapyforthetreatmentofcutaneousmalignanciesevaluationofearlyclinicalresponse